In its decision of 9 October 2026 (Biogaran v. Lundbeck, UPC_CFI_1587/2025), the Milan Central Division of the Unified Patent Court addressed this question in a revocation action concerning European patent EP 4 223 296, relating to the use of nalmefene to reduce alcohol consumption in a specific subgroup of alcohol-dependent patients defined by specific parameters.
🔹Novelty: more than identifying a patient subgroup
In line with established EPO case law (including T 19/86), the Court recalled that merely selecting a subset of patients does not necessarily establish novelty. The subgroup must be physiologically or pathologically distinct, with its defining characteristics functionally linked to a distinct therapeutic effect.
Here, the Court found that the claimed subgroup was associated with a more pronounced therapeutic response to nalmefene, an approach not directly and unambiguously disclosed in the prior art.
🔹Inventive step: more than a hope of success
Referring to Amgen v. Sanofi/Regeneron (UPC Court of Appeal, 25 November 2025) and its earlier decision of 4 May 2026 (UPC_CFI_552/2025), the Court distinguished a mere hope of success from a reasonable expectation of success grounded in scientific knowledge.
It also referred to Kodak v. Fujifilm (UPC Court of Appeal, 2 June 2026), confirming that the mere disclosure of relevant features in separate prior-art documents does not make their combination obvious without a reason to combine them.
In this case, the prior art provided no pointer towards the claimed patient selection, and the proposed combination of numerous disclosures was considered an exercise in hindsight.
The Court therefore dismissed the revocation action and maintained the patent in amended form, following the deletion of two dependent claims.
Practical takeaway: For pharmaceutical companies, protecting patient-subgroup inventions requires careful consideration of the therapeutic significance of the selected population and whether the prior art would have led the skilled person to that selection with a reasonable expectation of success.
October 2026